Commissioning Analytics: CCG Pathway Effectiveness Reports
Leveraging Commissioning Analytics Data to Create Access
The Challenge

Convincing Clinical Experts and Budget Holders of the need for change and creating sustainable relationships built on value and respect are fundamental challenges faced by healthcare companies today.

Overview

Working with a pharma client, Oberoi Consulting developed Clinical Commissioning Group (CCG) and practice level reports which delivered ‘pathway effectiveness assessments’ for a specific disease area.

Nationally published QOF and HES data was analysed to produce a gap analysis, to assess how many patients were not being treated to NICE & QOF targets.

Personalised CCG / CHP / LHB / LCG reports allowed the Healthcare Organisation to compare performance against national data in the following areas:

- Actual Intervention (patients treated / achieving target)
- Exception Reporting Rates (patients not included in QOF achievement)
- HES outcomes aligned to policy drivers

Practice data was available to assist the Healthcare organisation in prioritising and planning.

Accurate and timely information is mission critical when delivering better outcomes in the most cost-effective way and baseline information is key to clinical and business decision making within the new NHS.

The purpose of the reports was to provide Local Health Economies with insight and better understanding of a specific disease and the preventative treatment for patients who are at high risk of complications, in line with NICE Guidelines.

In addition they provided information on how preventative treatment impacts on key policy outcomes and associated costs; allowing Health Economies to review the effectiveness of their current disease pathway and make changes to improve performance and outcomes for their patients.

The UK wide reports were aimed at Area Teams, CCGs, Health Boards and Practices.
**Key Outcomes**

The pathway effectiveness assessment reports have created considerable market access to key stakeholders, influenced pathway redesign and enabled guideline implementation services to be initiated.